Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy

BACKGROUND. Endocrine resistant metastatic disease develops in ~20–25% of hormone-receptor positive (HR+) breast cancer (BC) patients despite endocrine therapy (ET) use. Upregulation of HER family receptor tyrosine kinases (RTKs) represent escape mechanisms in response to ET in some HR+ tumors. Shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Lubna Naaz, Jorns, Julie, Sun, Yunguang, Cheng, Yee Chung, Kamaraju, Sailaja, Burfeind, John, Gonyo, MaryBeth, Kong, Amanda, Patten, Caitlin, Yen, Tina, Cortina, Chandler, Carson, Ebony, Johnson, Nedra, Bergom, Carmen, Tsaih, Shirng-Wern, Banerjee, Anjishnu, Wang, Yu, Chervoneva, Inna, Weil, Elizabeth, Chitambar, Christopher R, Rui, Hallgeir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104267/
https://www.ncbi.nlm.nih.gov/pubmed/37066270
http://dx.doi.org/10.21203/rs.3.rs-2777910/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104267/
https://www.ncbi.nlm.nih.gov/pubmed/37066270
http://dx.doi.org/10.21203/rs.3.rs-2777910/v1

Ejemplares similares